WASHINGTON The Food and Drug Administration’s Pediatric Advisory Committee will meet on Nov. 27 to review the neurological and behavioral side effects in children who have taken the influenza treatment Tamiflu, according to Bloomberg.
This comes two years after the drug was linked to the deaths of at least a dozen Japanese children. Roche Holding, which manufactures the drug, claims the flu and not the drug caused the reported side effects in the children.
Nonetheless, governments are stockpiling the medication in case of a flu breakout.
The committee also plans to reviews reports linked to other medications such as Serevent, Provigil, Emtriva, Gleevec, Azopt and Betaxon.